Navid Shomali

Dr. Navid Shomali

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
FMFaroogh Marofi
Faroogh Marofi
RMRoza Motavalli
Roza Motavalli
VSVladimir A. Safonov
Vladimir A. Safonov
LTLakshmi Thangavelu
Lakshmi Thangavelu
AYAlexei Valerievich Yumashev
Alexei Valerievich Yumashev
FKFarhad Motavalli Khiavi
Farhad Motavalli Khiavi
Background: CARs are simulated receptors containing an extracellular single-chain variable fragment (scFv), a transmembrane domain, as well as an intracellular region of immunoreceptor tyrosine-based activation motifs (ITAMs) in association with a co-stimulatory signal. Main body: Chimeric antigen receptor (CAR) T cells are genetically engineered T cells to express a receptor for the recognition of the particular surface marker that has given rise to advances in the treatment of blood disorders. The CAR T cells obtain supra-physiological properties and conduct as “living drugs” presenting both immediate and steady effects after expression in T cells surface. But, their efficacy in solid tumor treatment has not yet been supported. The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and exhaustion, and as a result of the combined use of CARs and checkpoint blockade, as well as the suppression of other inhibitor factors in the microenvironment, very promising results were obtained from the reduction of T cell exhaustion. Conclusion: Nowadays, identifying and defeating the mechanisms associated with CAR T cell dysfunction is crucial to establish CAR T cells that can proliferate and lyse tumor cells severely. In this review, we discuss the CAR signaling and efficacy T in solid tumors and evaluate the most significant barriers in this process and describe the most novel therapeutic methods aiming to the acquirement of the promising therapeutic outcome in non-hematologic malignancies.

7 April 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
ANAdel Naimi
Adel Naimi
RMRebar N. Mohammed
Rebar N. Mohammed
ARAhmed Raji
Ahmed Raji
Supat ChupraditSupat Chupradit
Supat Chupradit
AYAlexei Valerievich Yumashev
Alexei Valerievich Yumashev
EREhsan Razeghian
Ehsan Razeghian
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint (IC) proteins, which act as a potent suppressor of the immune system by a myriad of mechanisms. After that, scientists focused on the immune checkpoint molecules mainly. Thereby, much effort was spent to progress novel strategies for suppressing these inhibitory axes, resulting in the evolution of immune checkpoint inhibitors (ICIs). Then, ICIs have become a promising approach and shaped a paradigm shift in tumor immunotherapies. CTLA-4 plays an influential role in attenuation of the induction of naïve and memory T cells by engagement with its responding ligands like B7-1 (CD80) and B7-2 (CD86). Besides, PD-1 is predominantly implicated in adjusting T cell function in peripheral tissues through its interaction with programmed death-ligand 1 (PD-L1) and PD-L2. Given their suppressive effects on anti-tumor immunity, it has firmly been documented that ICIs based therapies can be practical and rational therapeutic approaches to treat cancer patients. Nonetheless, tumor inherent or acquired resistance to ICI and some treatment-related toxicities restrict their application in the clinic. The current review will deliver a comprehensive overview of the ICI application to treat human tumors alone or in combination with other modalities to support more desired outcomes and lower toxicities in cancer patients.

29 April 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
AMAmirhossein Mardi
Amirhossein Mardi
ASAnastasia V. Shirokova
Anastasia V. Shirokova
RMRebar N. Mohammed
Rebar N. Mohammed
AKAli Keshavarz
Ali Keshavarz
AZAngelina O. Zekiy
Angelina O. Zekiy
MAMorteza Akbari
Morteza Akbari
Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered several challenges due to antigen heterogeneity, suboptimal CAR T-cell trafficking, and the immunosuppressive features of the tumor microenvironment (TME). Oncolytic virotherapy is a novel cancer therapy that employs competent or genetically modified oncolytic viruses (OVs) to preferentially proliferate in tumor cells. OVs in combination with CAR T-cells are promising candidates for overcoming the current drawbacks of CAR T-cell application in tumors through triggering immunogenic cell death (ICD) in cancer cells. ICD is a type of cellular death in which danger-associated molecular patterns (DAMPs) and tumor-specific antigens are released, leading to the stimulation of potent anti-cancer immunity. In the present review, we discuss the biological causes of ICD, different types of ICD, and the synergistic combination of OVs and CAR T-cells to reach potent tumor-specific immunity.

1 January 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
NSNaghmeh Shirafkan
Naghmeh Shirafkan
BMBehzad Mansoori
Behzad Mansoori
AMAli Mohammadi
Ali Mohammadi
NSNavid Shomali
Navid Shomali
MGMehri Ghasbi
Mehri Ghasbi
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

9 October 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MHMaryam Hemmatzadeh
Maryam Hemmatzadeh
NSNavid Shomali
Navid Shomali
YYYousef Yousefzadeh
Yousef Yousefzadeh
HMHamed Mohammadi
Hamed Mohammadi
AGAliyeh Ghasemzadeh
Aliyeh Ghasemzadeh
MYMehdi Yousefi
Mehdi Yousefi

26 August 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MGMehri Ghasabi
Mehri Ghasabi
BMBehzad Mansoori
Behzad Mansoori
AMAli Mohammadi
Ali Mohammadi
Pascal DuijfPascal Duijf
Pascal Duijf
NSNavid Shomali
Navid Shomali
Behzad BaradaranBehzad Baradaran
Behzad Baradaran